JP2020522508A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020522508A5 JP2020522508A5 JP2019566619A JP2019566619A JP2020522508A5 JP 2020522508 A5 JP2020522508 A5 JP 2020522508A5 JP 2019566619 A JP2019566619 A JP 2019566619A JP 2019566619 A JP2019566619 A JP 2019566619A JP 2020522508 A5 JP2020522508 A5 JP 2020522508A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- tumor
- antibody according
- subject
- identified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023127759A JP2023159179A (ja) | 2017-06-01 | 2023-08-04 | 抗ｐｄ－１抗体を用いる腫瘍の治療方法 |
| JP2025281525A JP2026053613A (ja) | 2017-06-01 | 2025-12-25 | 抗ｐｄ－１抗体を用いる腫瘍の治療方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762513831P | 2017-06-01 | 2017-06-01 | |
| US62/513,831 | 2017-06-01 | ||
| PCT/US2018/035670 WO2018223040A1 (en) | 2017-06-01 | 2018-06-01 | Methods of treating a tumor using an anti-pd-1 antibody |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023127759A Division JP2023159179A (ja) | 2017-06-01 | 2023-08-04 | 抗ｐｄ－１抗体を用いる腫瘍の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020522508A JP2020522508A (ja) | 2020-07-30 |
| JP2020522508A5 true JP2020522508A5 (https=) | 2021-07-26 |
| JP7780857B2 JP7780857B2 (ja) | 2025-12-05 |
Family
ID=62685228
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019566619A Active JP7780857B2 (ja) | 2017-06-01 | 2018-06-01 | 抗ｐｄ－１抗体を用いる腫瘍の治療方法 |
| JP2023127759A Pending JP2023159179A (ja) | 2017-06-01 | 2023-08-04 | 抗ｐｄ－１抗体を用いる腫瘍の治療方法 |
| JP2025281525A Pending JP2026053613A (ja) | 2017-06-01 | 2025-12-25 | 抗ｐｄ－１抗体を用いる腫瘍の治療方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023127759A Pending JP2023159179A (ja) | 2017-06-01 | 2023-08-04 | 抗ｐｄ－１抗体を用いる腫瘍の治療方法 |
| JP2025281525A Pending JP2026053613A (ja) | 2017-06-01 | 2025-12-25 | 抗ｐｄ－１抗体を用いる腫瘍の治療方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US11566073B2 (https=) |
| EP (1) | EP3630840A1 (https=) |
| JP (3) | JP7780857B2 (https=) |
| KR (2) | KR20240149982A (https=) |
| CN (2) | CN117462668A (https=) |
| WO (1) | WO2018223040A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1203971A1 (en) * | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| JP2018514550A (ja) | 2015-04-28 | 2018-06-07 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置 |
| EP4458417A3 (en) | 2015-08-11 | 2025-02-19 | Wuxi Biologics Ireland Limited | Novel anti-pd-1 antibodies |
| KR20240149982A (ko) | 2017-06-01 | 2024-10-15 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체를 사용하여 종양을 치료하는 방법 |
| SG11202007590TA (en) * | 2018-02-13 | 2020-09-29 | Merck Sharp & Dohme | Methods for treating cancer with anti-pd-1 antibodies |
| CN111821434A (zh) * | 2019-04-17 | 2020-10-27 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体在制备治疗实体瘤的药物中的用途 |
| JP2022514952A (ja) * | 2018-12-19 | 2022-02-16 | ストラータ オンコロジー， インコーポレイテッド | チェックポイント阻害薬応答性がんを有する対象を検出及び処置する方法 |
| CN114269376A (zh) * | 2019-05-03 | 2022-04-01 | 豪夫迈·罗氏有限公司 | 用抗pd-l1抗体治疗癌症的方法 |
| US12275986B2 (en) * | 2020-01-06 | 2025-04-15 | Duke University | Biomarkers associated with checkpoint immune therapy and methods of using same |
| CN110923329B (zh) * | 2020-02-06 | 2020-05-12 | 至本医疗科技（上海）有限公司 | Fgfr4点突变在预测非小细胞肺癌患者对免疫检查点抑制剂疗法敏感性中的应用 |
| CN111440822A (zh) * | 2020-04-16 | 2020-07-24 | 苏州大学附属第二医院 | 一种突变lats1质粒的构建与应用 |
| KR20230093282A (ko) | 2020-10-23 | 2023-06-27 | 브리스톨-마이어스 스큅 컴퍼니 | 폐암에 대한 lag-3 길항제 요법 |
| CN112961920A (zh) * | 2021-03-24 | 2021-06-15 | 臻和(北京)生物科技有限公司 | 一种预测肝胆肿瘤患者免疫检查点抑制剂联合靶向治疗疗效的方法及产品 |
| JP7806990B2 (ja) * | 2021-08-10 | 2026-01-27 | 国立大学法人 新潟大学 | 内胚葉嚢胞の悪性化に関連する遺伝子の検出方法 |
| CN113943806A (zh) * | 2021-11-04 | 2022-01-18 | 至本医疗科技（上海）有限公司 | 预测肺腺癌患者对免疫疗法敏感性的生物标志物、应用和装置 |
| US20250349434A1 (en) * | 2022-04-26 | 2025-11-13 | Hoffmann-La Roche Inc. | Methods and systems for predicting cancer therapy response |
| CN114931637B (zh) * | 2022-06-27 | 2025-02-18 | 中山大学中山眼科中心 | Pdl1抗体在角膜新生血管疾病中的应用 |
| CN115825441B (zh) * | 2023-01-30 | 2023-05-26 | 上海秤信生物科技有限公司 | 预测肺癌三期患者的免疫新辅助疗效的自身抗体标志物 |
| WO2025085707A1 (en) * | 2023-10-19 | 2025-04-24 | Tesaro, Inc. | Methods of treating cancer with anti-pd-1 agents |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL354286A1 (en) | 1999-08-23 | 2003-12-29 | Dana-Farber Cancer Institutedana-Farber Cancer Institute | Pd-1, a receptor for b7-4, and uses therefor |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| HK1203971A1 (en) | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| KR20220084444A (ko) | 2012-05-31 | 2022-06-21 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
| SMT202100065T1 (it) | 2013-05-02 | 2021-03-15 | Anaptysbio Inc | Anticorpi diretti contro la proteina della morte programmata (pd-1) |
| WO2014194302A2 (en) | 2013-05-31 | 2014-12-04 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| SG10201804945WA (en) | 2013-12-12 | 2018-07-30 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| DE112014005975T5 (de) * | 2013-12-17 | 2016-09-15 | Kymab Limited | Menschliche Ziele |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| PE20170255A1 (es) | 2014-01-24 | 2017-03-22 | Dana Farber Cancer Inst Inc | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas |
| WO2015116868A2 (en) * | 2014-01-29 | 2015-08-06 | Caris Mpi, Inc. | Molecular profiling of immune modulators |
| EP3134546A4 (en) * | 2014-04-24 | 2017-12-06 | Dana-Farber Cancer Institute, Inc. | Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response |
| DK3237446T3 (en) | 2014-12-22 | 2021-07-26 | Pd 1 Acquisition Group Llc | Anti-PD-1-antistoffer |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| US20180155429A1 (en) * | 2015-05-28 | 2018-06-07 | Bristol-Myers Squibb Company | Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody |
| WO2016197367A1 (en) | 2015-06-11 | 2016-12-15 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| HUE068868T2 (hu) | 2015-07-30 | 2025-02-28 | Macrogenics Inc | PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások |
| WO2017020291A1 (en) | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| EP4458417A3 (en) | 2015-08-11 | 2025-02-19 | Wuxi Biologics Ireland Limited | Novel anti-pd-1 antibodies |
| WO2017024515A1 (en) | 2015-08-11 | 2017-02-16 | Wuxi Biologics (Cayman) Inc. | Novel anti-pd-1 antibodies |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| AU2016317915B2 (en) | 2015-09-01 | 2021-02-18 | Agenus Inc. | Anti-PD-1 antibodies and methods of use thereof |
| US20170114098A1 (en) | 2015-09-03 | 2017-04-27 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| IL260021B (en) | 2015-12-14 | 2022-09-01 | Macrogenics Inc | Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them |
| US11814679B2 (en) | 2016-01-11 | 2023-11-14 | Eli Lilly And Company | Interleukin-10 production of antigen-specific CD8+ T cells and methods of use of same |
| CN108029076B (zh) | 2016-02-02 | 2020-03-10 | 华为技术有限公司 | 确定发射功率的方法、用户设备和基站 |
| WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| CN109476753A (zh) | 2016-06-03 | 2019-03-15 | 百时美施贵宝公司 | 用于治疗肿瘤的方法的抗-pd-1抗体 |
| KR20240149982A (ko) | 2017-06-01 | 2024-10-15 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체를 사용하여 종양을 치료하는 방법 |
| CN113249483B (zh) * | 2021-06-10 | 2021-10-08 | 北京泛生子基因科技有限公司 | 一种检测肿瘤突变负荷的基因组合、系统及应用 |
-
2018
- 2018-06-01 KR KR1020247032911A patent/KR20240149982A/ko active Pending
- 2018-06-01 JP JP2019566619A patent/JP7780857B2/ja active Active
- 2018-06-01 EP EP18733121.0A patent/EP3630840A1/en active Pending
- 2018-06-01 WO PCT/US2018/035670 patent/WO2018223040A1/en not_active Ceased
- 2018-06-01 CN CN202311104154.0A patent/CN117462668A/zh active Pending
- 2018-06-01 KR KR1020197038639A patent/KR102714702B1/ko active Active
- 2018-06-01 CN CN201880035434.1A patent/CN110678483B/zh active Active
- 2018-06-01 US US16/617,725 patent/US11566073B2/en active Active
-
2023
- 2023-01-30 US US18/161,713 patent/US12227576B2/en active Active
- 2023-08-04 JP JP2023127759A patent/JP2023159179A/ja active Pending
-
2025
- 2025-01-09 US US19/015,341 patent/US20250145713A1/en active Pending
- 2025-12-25 JP JP2025281525A patent/JP2026053613A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020522508A5 (https=) | ||
| Patel et al. | The role of poly (ADP-ribose) polymerase inhibitors in the treatment of cancer and methods to overcome resistance: a review | |
| Xie et al. | KRAS-mutant non-small cell lung cancer: an emerging promisingly treatable subgroup | |
| Jin et al. | Identification of genetic mutations in cancer: challenge and opportunity in the new era of targeted therapy | |
| Awad et al. | Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis | |
| Lamberti et al. | Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer | |
| Daniel et al. | Temozolomide induced hypermutation in glioma: evolutionary mechanisms and therapeutic opportunities | |
| Beaver et al. | PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system | |
| Pu et al. | Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance | |
| Burgess et al. | The therapeutic potential of DNA damage repair pathways and genomic stability in lung cancer | |
| Becker et al. | Retreatment with erlotinib: regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment | |
| Zhao et al. | Mismatch repair deficiency endows tumors with a unique mutation signature and sensitivity to DNA double-strand breaks | |
| JP2013523744A5 (https=) | ||
| US20220160714A1 (en) | Methods for treating colorectal cancer | |
| JP2017214436A5 (https=) | ||
| Nelson et al. | Implications of DNA damage and DNA repair on human diseases | |
| Bush et al. | AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer models | |
| ES2686549T3 (es) | Método para seleccionar una triterapia personalizada para el tratamiento del cáncer | |
| Nishio et al. | RELAY, ramucirumab plus erlotinib (RAM+ ERL) in untreated metastatic EGFR-mutant NSCLC (EGFR+ NSCLC): association between TP53 status and clinical outcome | |
| Xue et al. | Therapeutic evaluation of palbociclib and its compatibility with other chemotherapies for primary and recurrent nasopharyngeal carcinoma | |
| Cui et al. | Expert opinion on translational research for advanced glioblastoma treatment | |
| CN115998872A (zh) | 一种含有抑制核酸内切酶功能的药物及其抗肿瘤的用途 | |
| Xiong et al. | Comutations in DDR pathways predict atezolizumab response in non-small cell lung cancer patients | |
| Valet et al. | Response to the combination of osimertinib, dabrafenib, and trametinib in leptomeningitis from EGFR-mutant NSCLC with acquired BRAF V600E mutation: a case report | |
| Li et al. | Targeting BRCA‐mutant biliary tract cancer: Current evidence and future perspectives |